ACR Meeting Abstracts

ACR Meeting Abstracts

Abstract Number: 1040

Clinic Personnel Perceptions Were Favorable for the Implementation of a Patient Decision-Aid for a Diverse Systemic Lupus Erythematosus Population: A Study in 15 U.S. Rheumatology Clinics

Jasvinder Singh1, Larry Hearld2, Walter Chatham3, Sonali Narain4, Narender Annapureddy5, Diane Kamen6, Kimberly Trotter7, vikas Majithia8, Cathy Lee Ching9, Zineb Aouhab10, Swamy Venuturupalli11, Daniel Wallace12, rosalind Ramsey-Goldman13, Alfred Kim14, Maureen McMahon15, S. Sam Lim16, Kalpana Bhairavarasu17, Alexa Meara18 and Kenneth Kalunian19, 1Baylor College of Medicine, Birmingham, AL, 2University of Alabama at Birmingham (UAB), Birmingham, AL, 3University of Nevada, Las Vegas, Las Vegas, NV, 4Northwell Health, Great Neck, NY, 5Vanderbilt University Medical Center, Nashville, TN, 6Medical University of South Carolina, Charleston, SC, 7University of Chicago, Chicago, IL, 8University of Missisippi Medical Center (UMC), Jackson, MS, 9UMMC, Jackson, MS, 10Loyola University Medical Center, Oak Brook, IL, 11Attune Health, Beverly Hills, CA, 12Cedars Sinai Medical Center, Studio City, CA, 13Northwestern University, Chicago, IL, 14Washington University School of Medicine, Division of Rheumatology, Department of Medicine, St Louis, MO, 15UCLA David Geffen School of Medicine, Los Angeles, CA, 16Emory University, Atlanta, GA, 17Baylor College of Medicine, Sugar Land, TX, 18The Ohio State University Wexner Medical Center, COLUMBUS, OH, 19University of California San Diego, La Jolla, CA

Meeting: ACR Convergence 2024

Keywords: , , , ,

Session Information

Date: Sunday, November 17, 2024

Title: Health Services Research – ACR/ARP Poster II

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: To understand clinic personnel feedback regarding the implementation of a self-administered patient decision-aid (PtDA) for lupus in regular, outpatient rheumatology clinics.

Methods: We provided self-administered lupus PtDA through a touchscreen tablet in clinics, a weblink or as smartphone application, in 15 rheumatology clinics across the U.S. Clinic personnel outcomes were assessed at baseline, 12- and 24-month follow-up based on validated surveys included: (1) Organizational Readiness to Implement Change (ORIC; score range 1-5); (2) Team Learning and Psychological Safety Survey (TLPSS; score range 1-7); and (3) perceived lupus PtDA appropriateness, acceptability, feasibility, success, permanence, and sustenance (all scale score range of 1-5). Higher scores are consistent with best/most desirable outcomes.

Results: Clinic personnel’s (n=182-184) baseline ORIC commitment and efficacy scores (range 1-5) ranged from 3.5 to 4.2, and 3.4 to 4.4 for sites, respectively; TLPSS scores (range 1-7) were 3.9 to 5.5 for internal learning, 3.7 to 5.6 for external learning, and 4.3 to 6.2 for psychological safety.

Clinic personnel perceived lupus PtDA outcomes optimally at baseline with all scale score range of 1-5, higher values indicating better outcome: (1) appropriateness, 3.43 (SD, 0.86); (2) acceptability, 3.53 (SD, 0.83); (3) feasibility, 3.44 (SD, 0.71); (4) success, 3.41 (SD, 0.73); (5) permanence, 3.22 (SD, 0.74).

Conclusion: We found that clinic personnel rated various aspects of the lupus PtDA well during its implementation in rheumatology outpatient clinics. It remains to be seen as to whether barriers to sustaining this lupus PtDA, which is freely available in the public domain now, can be overcome in busy clinic sessions. We also need to understand if different barriers and facilitators operate in private versus academic rheumatology clinics.

Funding:
Research reported in this work was funded through a Patient-Centered Outcomes Research Institute (PCORI) Award (SDM-2017C2-8224). The statements in this publication are solely the responsibility of the authors and do not necessarily represent the views of PCORI, its Board of Governors, or the Methodology Committee.

Disclosures: J. Singh: Adaptimmune Therapeutics, 2, Adept Field Solutions, 2, Aebona Pharmaceuticals, 11, Amarin, Viking and Moderna pharmaceuticals, 11, Atai life sciences, Kintara therapeutics, Intelligent Biosolutions, Acumen pharmaceutical, TPT Global Tech, Vaxart pharmaceuticals, Atyu biopharma, Ad, 11, Charlotte's Web Holdings, 11, Clinical Care options, 2, Enzolytics Inc, 11, Fidia, 2, Focus forward, 2, GeoVax Labs, 11, Intuitive Surgical Inc./Philips Electronics North America, 12, food and beverage payments, Jupiter Life Science, 2, MedIQ, 2, Medscape, 2, Medusas, 2, Navigant consulting, 2, Pieris Pharmaceuticals, 11, PK Med, 2, Practice Point communications, 2, Putnam associates, 2, ROMTech, Atheneum, Clearview healthcare partners, American College of Rheumatology, Yale, Hulio, Horizon Pharmaceuticals/DINORA, Frictionless Solution, 2, Schipher, 2, Seres Therapeutics, 11, speaker’s bureau of Simply Speaking, 6, Tonix Parmaceuticals, 11, Trio Health, 2, Two Labs Inc, 2, UBM LLC, 2, WebMD, 2, Zimmer Biomet Holdings, 5; L. Hearld: None; W. Chatham: None; S. Narain: None; N. Annapureddy: None; D. Kamen: Alpine Immune Sciences, 1, Bristol Myers Squibb (BMS), 1; K. Trotter: None; v. Majithia: None; C. Lee Ching: None; Z. Aouhab: None; S. Venuturupalli: None; D. Wallace: None; r. Ramsey-Goldman: None; A. Kim: Amgen, 2, ANI Pharmaceuticals, 2, AstraZeneca, 5, Atara Bio, 2, Aurinia Pharmaceuticals, 2, Cargo Therpeutics, 2, Exagen Diagnostics, 2, 6, GSK, 2, 5, 6, Kypha, 2, 4, 10, Miltenyi Biotech, 2, Novartis, 5, Pfizer, 2, Synthekine, 2, Techtonic Therapeutics, 2, The Rheumatology Education Group, 6; M. McMahon: Amgen, 2, Artivia, 2, Astra Zeneca, 6, Aurinia, 6, Bristol-Myers Squibb(BMS), 2, Genentech, 2, GSK, 2, 6; S. Lim: Accordant, 2, AstraZeneca, 2, Biogen, 5, BMS, 5, Gilead, 5, GSK, 2, Novartis, 5, UCB, 5; K. Bhairavarasu: None; A. Meara: None; K. Kalunian: None.

To cite this abstract in AMA style:

Singh J, Hearld L, Chatham W, Narain S, Annapureddy N, Kamen D, Trotter K, Majithia v, Lee Ching C, Aouhab Z, Venuturupalli S, Wallace D, Ramsey-Goldman r, Kim A, McMahon M, Lim S, Bhairavarasu K, Meara A, Kalunian K. Clinic Personnel Perceptions Were Favorable for the Implementation of a Patient Decision-Aid for a Diverse Systemic Lupus Erythematosus Population: A Study in 15 U.S. Rheumatology Clinics [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/clinic-personnel-perceptions-were-favorable-for-the-implementation-of-a-patient-decision-aid-for-a-diverse-systemic-lupus-erythematosus-population-a-study-in-15-u-s-rheumatology-clinics/. Accessed .

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/clinic-personnel-perceptions-were-favorable-for-the-implementation-of-a-patient-decision-aid-for-a-diverse-systemic-lupus-erythematosus-population-a-study-in-15-u-s-rheumatology-clinics/